Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome

Genes Chromosomes and Cancer

Volumn 53, Issue 5, 2014, Pages 402-410

  Volkert, Sarah ^a   Kohlmann, Alexander ^a   Schnittger, Susanne ^a   Kern, Wolfgang ^a   Haferlach, Torsten ^a   Haferlach, Claudia ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME BANDING PATTERN; CHROMOSOME DELETION 5; CLONAL EVOLUTION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; MIDDLE AGED; MONOSOMY; MONOSOMY 5; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; VERY ELDERLY;

ABNORMAL KARYOTYPE; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CLONAL EVOLUTION; EARLY GROWTH RESPONSE PROTEIN 1; GENETIC ASSOCIATION STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84895928570     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22151     Document Type: Article

References (23)

1. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman J, Harris NL. 2001. Myelodysplastic syndromes. In: Jaffe ES, Harris N, Stein H, Vardiman J, editors. World Health Organization of Tumors, Pathology & Genetics, Tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press. pp. 61-73.
2. Brunning R, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, Vardiman JW, Hellström-Lindberg E. 2008. Myelodysplastic syndromes. In: Swerdlow S, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press. pp. 87-93.
3. Chun K, Hagemeijer A, Iqbal A, Slovak ML. 2010. Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study. Leuk Res 34:160-165.
4. Douet-Guilbert N, De Braekeleer E, Basinko A, Herry A, Gueganic N, Bovo C, Trillet K, Dos Santos A, Le Bris MJ, Morel F, Eveillard JR, Berthou C, De Braekeleer M. 2012. Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients. Leukemia 26:1695-1697.
5. Ebert BL. 2009. Deletion 5q in myelodysplastic syndrome: A paradigm for the study of hemizygous deletions in cancer. Leukemia 23:1252-1256.
6. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK. 2010. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365.
7. Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F, Schmid C, Wendtner CM, Staib P, Serve H, Kreuzer KA, Kern W, Haferlach T, Haferlach C. 2012. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 120:2963-2972.
8. Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, Hedlund A, Hast R, Schlegelberger B, Porwit A, Hellstrom-Lindberg E, Mufti GJ. 2011. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 29:1971-1979.
9. Jerez A, Gondek LP, Jankowska AM, Makishima H, Przychodzen B, Tiu RV, O'Keefe CL, Mohamedali AM, Batista D, Sekeres MA, McDevitt MA, Mufti GJ, Maciejewski JP. 2012. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol 30:1343-1349.
10. La Starza R, Matteucci C, Gorello P, Brandimarte L, Pierini V, Crescenzi B, Nofrini V, Rosati R, Gottardi E, Saglio G, Santucci A, Berchicci L, Arcioni F, Falini B, Martelli MF, Sambani C, Aventin A, Mecucci C. 2010. NPM1 deletion is associated with gross chromosomal rearrangements in leukemia. PLoS One 5:e12855.
11. Löffler H, Rastetter J, Haferlach T. 2010. Atlas of Clinical Hematology. Heidelberg: Springer.
12. Mallo M, Cervera J, Schanz J, Such E, Garcia-Manero G, Luno E, Steidl C, Espinet B, Vallespi T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstocker M, Hernandez JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martin ML, Valent P, Collado R, Haferlach C, Fonatsch C, Lubbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L, Sanz MA, Valencia A, Florensa L, Sanz GF, Haase D, Sole F. 2011. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 25:110-120.
13. Mallo M, del Rey M, Ibanez M, Calasanz MJ, Arenillas L, Larrayoz MJ, Pedro C, Jerez A, Maciejewski J, Costa D, Nomdedeu M, Diez-Campelo M, Lumbreras E, Gonzalez-Martinez T, Marugan I, Such E, Cervera J, Cigudosa JC, Alvarez S, Florensa L, Hernandez JM, Sole F. 2013. Response to lenalidomide in myelodysplastic syndromes with del(5q): Influence of cytogenetics and mutations. Br J Haematol 162:74-86.
14. Nofrini V, La Starza R, Crescenzi B, Pierini V, Barba G, Mecucci C. 2012. Different boundaries characterize isolated and non-isolated 5q deletions in myelodysplastic syndromes and acute myeloid leukemias. Haematologica 97:792-794.
15. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK. 2006. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 20:1943-1949.
16. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. 2008. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 22:240-248.
17. Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstocker M, Nosslinger T, Valent P, Giagounidis A, Aul C, Lubbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. 2012. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30:820-829.
18. Schoch C, Haferlach T, Bursch S, Gerstner D, Schnittger S, Dugas M, Kern W, Löffler H, Hiddemann W. 2002a. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 35:20-29.
19. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T. 2002b. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases. Leukemia 16:53-59.
20. Shaffer LG, McGowan-Jordan J, Schmid M. 2013. ISCN 2013: An International System for Human Cytogenetic Nomenclature. Basel, New York: Karger.
21. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press.
22. Washington LT, Doherty D, Glassman A, Martins J, Ibrahim S, Lai R. 2002. Myeloid disorders with deletion of 5q as the sole karyotypic abnormality: The clinical and pathologic spectrum. Leuk Lymphoma 43:761-765.
23. Wolff DJ, Bagg A, Cooley LD, Dewald GW, Hirsch BA, Jacky PB, Rao KW, Rao PN. 2007. Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn 9:134-143.